Payment overview · 2025
General Payments
$561.79
30 reported records · 14 companies
Healthcare provider profile · identity verified
Daniel L. Johnson, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LEBANON, MO · NPI 1124199690
Verified facts
What the public records show
CMS Open Payments records show Daniel L. Johnson, FNP received $561.79 in general payments during 2025 across 30 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 21.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nurtec Odt, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $117.79 | 21.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.14 | 13.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.70 | 9.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.79 | 8.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.38 | 7.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.51 | 6.5% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $34.65 | 6.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.35 | 5.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.42 | 5.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $24.24 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.65 | 3.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.24 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.21 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.72 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $561.79 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $117.79 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $75.14 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.35 | 2 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $33.35 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.35 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $33.35 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
151 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 389 | 101 |
| Lisinopril | Lisinopril | 306 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 62 |
| Gabapentin | Gabapentin | 269 | 55 |
| Tramadol Hcl | Tramadol Hcl | 263 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 83 |
| Metformin Hcl | Metformin Hcl | 224 | 60 |
| Furosemide | Furosemide | 210 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 44 |
| Omeprazole | Omeprazole | 177 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 57 |
| Glimepiride | Glimepiride | 153 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 41 |
| Eliquis | Apixaban | 151 | 30 |
| Potassium Chloride | Potassium Chloride | 148 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 124 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 123 | 26 |
| Losartan Potassium | Losartan Potassium | 122 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 26 |
| Carvedilol | Carvedilol | 102 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 98 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 36 |
| Trazodone Hcl | Trazodone Hcl | 94 | 25 |
| Sertraline Hcl | Sertraline Hcl | 93 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 19 |
| Famotidine | Famotidine | 90 | 23 |
| Jardiance | Empagliflozin | 90 | 13 |
| Ozempic | Semaglutide | 88 | 17 |
| Montelukast Sodium | Montelukast Sodium | 86 | 17 |
| Baclofen | Baclofen | 85 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 21 |
| Buspirone Hcl | Buspirone Hcl | 77 | 14 |
| Chlorthalidone | Chlorthalidone | 77 | 22 |
| Meloxicam | Meloxicam | 76 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 20 |
| Simvastatin | Simvastatin | 68 | 16 |
| Mirtazapine | Mirtazapine | 66 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 14 |
| Lorazepam | Lorazepam | 62 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 17 |
| Prednisone | Prednisone | 61 | 25 |
| Azithromycin | Azithromycin | 60 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 15 |
| Methylprednisolone | Methylprednisolone | 59 | 51 |
| Spironolactone | Spironolactone | 54 | 16 |
| Allopurinol | Allopurinol | 53 | 13 |
| Metformin Hcl Er | Metformin Hcl | 53 | 13 |
| Atenolol | Atenolol | 52 | 11 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | 13 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Lovastatin | Lovastatin | 47 | 15 |
| Naproxen | Naproxen | 47 | 12 |
| Alprazolam | Alprazolam | 46 | 13 |
| Benazepril Hcl | Benazepril Hcl | 46 | 12 |
| Nabumetone | Nabumetone | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 13 |
| Finasteride | Finasteride | 43 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Piroxicam | Piroxicam | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 12 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $561.79 · 30 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, CAPVAXIVE, DAYBUE, Dexcom G6 Transmitter, ENFLONSIA, FARXIGA, FREESTYLE LIBRE, GARDASIL 9, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VAXNEUVANCE, VRAYLAR, XIFAXAN, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error